Published online by Cambridge University Press: 16 April 2020
Factors influencing outcomes of depression in clinical practice, especially health-related quality of life (HRQoL), are poorly understood. The Factors Influencing Depression Endpoints Research (FINDER) study is a European prospective, observational study designed to estimate the HRQoL of adults with a clinically diagnosed depressive episode at baseline, and 3 and 6 months after commencing antidepressant medication. We report here the study design and baseline patient characteristics.
HRQoL was assessed by the 36-item Short-Form Health Survey (SF-36) and European Quality of Life-5 Dimensions (EQ-5D). Patient ratings on Hospital Anxiety and Depression Scale (HADS) and pain Visual Analogue Scale (VAS) were also obtained. Results (n = 3468) showed that SF-36 mental component summary (mean 22.2) was more than two SDs below general population norms (mean 50.0) and one SD below clinical depression norms (mean 34.8); the physical component summary (mean 46.1) was similar to general population (mean 50.0) and clinical depression norms (mean 45.0). Mean EQ-5D scores were also lower than general population norms. Mean HADS-Depression and -Anxiety subscores were 12.3 and 13.0, respectively. Fifty-six percent of patients reported an overall pain VAS score of at least 30 mm and 70% of these patients had no physical explanation for their pain.
Further investigation into factors associated with HRQoL in depression after treatment initiation is warranted.
FINDER was funded by Eli Lilly and Company Limited, Windleham, UK and Boehringer Ingelheim GmbH, Ingelheim, Germany.
Dr Paul Gandhi was employed by Eli Lilly and Company Limited, Basingstoke, UK at the time the research was performed.
Tel.: +44 1276 483028 (office); fax: +44 (0) 1276 483192.
Tel.: +34 923 12 65 96/97 (office); fax: +34 923 26 54 82.
Tel.: +33 142 34 84 35 (office); fax: +33 142 34 84 33.
Tel.: +32 163 48705 (office); fax: +32 163 48700.
Tel.: +39 0532 236 409 (office); fax: +39 0532 212240.
Tel.: +49 6132 779 3362 (office); fax: +49 6132 774233.
Tel.: +44 1276 483755 (office); fax: +44 (0) 1276 483711.
Tel.: +44 20 8746 8733; fax: +44 (0) 20 8746 8711.
Tel.: +44 1276 483293 (office); fax: +44 (0) 1276 484800.
Tel.: +44 20 7848 0150 (office); fax: +44 (0) 20 7848 0333.
To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Find out more about the Kindle Personal Document Service.
To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.
To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.
Comments
No Comments have been published for this article.